In 2021, biotechs have been particularly highlighted, although some have fallen behind in their clinical development. These delays, added to the criticality of the progress of clinical studies, explain the strong needs expected in 2022, particularly in clinical and medical operations functions. In addition, the regulatory affairs functions for drugs and medical devices will remain crucial in 2022. These are key functions, essential during clinical development to obtain marketing authorization or CE marking, but also to maintain these products on the market.